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Palliative Care in Congestive Heart Failure
Sarah J. Goodlin, MD
Salt Lake City, Utah
Symptoms and compromised quality of life prevail throughout the course of heart failure (HF) and thus should
be specifically addressed with palliative measures. Palliative care for HF should be integrated into comprehen-
sive HF care, just as evidence-based HF care should be included in end-of-life care for HF patients. The neurohor-
monal and catabolic derangements in HF are at the base of HF symptoms. A complex set of abnormalities can
be addressed with a variety of interventions, including evidence-based HF care, specific exercise, opioids, treat-
ment of sleep-disordered breathing, and interventions to address patient and family perceptions of control over
their illness. Both potential sudden cardiac death and generally shortened length of life by HF should be ac-
knowledged and planned for. Strategies to negotiate communication about prognosis with HF patients and their
families can be integrated into care. Additional evidence is needed to direct care at the end of life, including use
of HF medications, and to define management of multiple sources of distress for HF patients and their
families. (J Am Coll Cardiol 2009;54:386–96) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.078a
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deart failure (HF) is an increasingly prevalent clinical
yndrome that limits length of life and profoundly impacts
unction and quality of life. Recent epidemiologic analysis
emonstrates increasing incidence and improved survival of
ersons with HF, resulting in a growing population of
ndividuals living with HF, who by definition are symptom-
tic. Heart failure is responsible for significant health care
ystem and individual burden. As therapies for HF improve
urvival, growing numbers of HF patients live with this
urden; many have advanced HF, and large numbers, by
irtue of being old, have comorbid conditions or are frail.
Although the discipline of palliative care began with a
ocus almost exclusively on end-of-life care, it was recon-
eptualized as recognition grew of the multiple domains of
istress patients with life-limiting illnesses and their fami-
ies experience throughout the course of illness. Significant
ymptoms and psychosocial distress begin during treatments
ntending to extend life or to cure potentially life-limiting
llness. The World Health Organization modified its defi-
ition in 2002 to state that palliative care should be provided
early in the course of illness, in conjunction with other
herapies that are intended to prolong life” (1). Palliative
are includes multiple disciplines to address distress from
ymptoms and other aspects of the illness in the patient and
n the family who are treated as a unit, as the well-being of
ne impacts the other (2). Communication with the patient
nd family and patient-centered decision making are inte-
ral to palliative care. Consensus panels and guidelines
rom Patient-Centered Education and Research, Salt Lake City, Utah. Dr. Goodlin
as received research grants from Boston Scientific and St. Jude Medical Foundation.a
Manuscript received October 5, 2008; revised manuscript received February 6,
009, accepted February 9, 2009.dvocated provision of palliative or supportive care concur-
ent with efforts to prolong life in HF (3), and at the end of
ife (4,5).
This paper will review the current understanding of
ymptom etiology and palliation in HF, and practical
spects of communication and end-of-life care.
omprehensive HF Care
atients with HF generally are symptomatic for some time
efore presenting for evaluation and receiving the diagnosis
f HF. With initiation of appropriate medications, diet and
uid management, and other interventions, the symptom
urden may diminish, but for many patients, exertion
emains limited, general fatigue persists, and social struc-
ures, including work and interpersonal relationships, are
ltered.
Palliative or supportive care to address symptom, psycho-
ocial, or existential distress and strategies to manage and
ope with HF should be provided concurrently with
vidence-based disease-modifying interventions in compre-
ensive HF care. Figure 1 and Table 1 depict a scheme for
onceptualizing comprehensive HF care. Early in HF ther-
py, supportive efforts focus on education for the patient and
amily about HF and self-management. Diuresis and
vidence-based therapies achieve a plateau of improved
unction. Even when a plateau of improved function is
chieved, the patient and family will benefit from efforts that
mprove symptoms and assist the patient and family in
oping with their HF and its impact on their lives. Heart
ransplantation or destination therapy ventricular assist
evices improve function for patients for a period and carry
different burden of chronic illness. At the end of life or
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July 28, 2009:386–96 Palliative Care for HFhen significant physical frailty or comorbidities predomi-
ate, the major focus of care is palliation, but some HF
herapies remain important. Heart failure differs from can-
er in which potentially curative treatments are discontinued as
he patient reaches the end stage.
Communication and decision making between clinicians
nd patients about therapies and devices must also be
ntegrated into comprehensive HF care. Education and
iscussions ideally occur over time linked to what the
atient values, and may require refreshing or revision at
urning points in the patient’s course.
ho should provide palliative care? Primary care clini-
ians provide the majority of HF care, thus they must ally
ith expert HF and palliative care clinicians to provide
omprehensive HF care. All cardiologists and HF specialists
hould align with other disciplines to provide comprehen-
ive HF care.
In large centers, palliative care might be provided by a
pecific interdisciplinary team that focuses on relief of
uffering (physical, psychosocial, and spiritual) distinct from
nd in addition to HF care. In general, however, creating a
ichotomy with palliative care as a supplement to life-
rolonging management is inappropriate to HF (6). Rather,
omprehensive management of HF should integrate pallia-
ive or supportive care with the evidence-based medications,
evices, and surgeries that intend to address HF pathophys-
ology, precisely because the physical and psychiatric distress
nd social issues are intertwined with HF pathophysiology.
herapies addressing HF pathophysiology that improve
urvival and cardiac function simultaneously palliate HF-
elated symptoms.
tiology of symptoms in HF. Heart failure patients expe-
ience symptoms of fatigue and lack of energy, dyspnea,
Figure 1 Schematic Depiction of Comprehensive Heart Failure
Figure illustration by Rob Flewell.epression, pain, and cognitive
mpairment, among other prob-
ems (7). The etiology of HF
ymptoms is complex and in-
ompletely understood. Al-
hough most patients have wors-
ned dyspnea with episodes of
olume overload, HF-related
yspnea and exertional fatigue
re not directly related to pulmo-
ary capillary wedge pressure or
ardiac output, rather to broader,
ystemic effects of HF, including
eneralized myopathy (8). Some
ymptoms may overlap with co-
orbid problems, which are par-
icularly prevalent in older indi-
iduals with HF (9). Symptoms
eported by HF patients are sig-
ificantly impacted by depression and by the patients’
erceived control over their condition (10).
Symptoms have been studied primarily in HF due to left
entricular systolic dysfunction (LVSD). Similar pathologic
bnormalities in inflammatory and neuroendocrine func-
ion are seen in heart failure with normal ejection fraction
HFnEF, also called “preserved systolic function” and
diastolic dysfunction”).
Figure 2 schematically presents the pathophysiologic
hanges of HF and their relation to symptoms. Regardless
f etiology, HF is characterized by alterations in the
enin-angiotensin-aldosterone, sympathetic, and other hor-
onal systems, resulting in a catabolic state (11). Proin-
ammatory cytokines are activated in HF, leading to insulin
Abbreviations
and Acronyms
CPAP  continuous
positive airway pressure
ESAS  Edmonton
Symptom Assessment
System
HF  heart failure
HFnEF  heart failure with
normal ejection fraction
LVSD  left ventricular
systolic dysfunction
NYHA  New York Heart
Association
SCD  sudden cardiac
death
SSRI  selective serotonin
reuptake inhibitorCare
Comprehensive HF CareTable 1 Comprehensive HF Care
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5
Initial symptoms of HF develop and
HF treatment is initiated
Plateau of variable length reached with initial
medical management, or following
mechanical support or heart transplant
Functional status declines with variable slope;
intermittent exacerbations of HF that
respond to rescue efforts
Stage D HF, with refractory symptoms and limited
function
End of life
NYHA functional
classification
II–III II–IV IIIB IV IV
HF care and
interventions
● Identify etiology of HF
● Eliminate precipitating factors
and causative conditions
● Diuretics¡euvolemia
● ACE inhibitor
● Beta-blocker
● Evaluate for coexistent
conditions1
● Spironolactone if NYHA functional class
III–IV
● Digoxin if NYHA functional class III–IV
and LVEF 35%
● Hydralazine/nitrates?
● Evaluate and treat for sleep-disordered
breathing
● ICD if EF 35% and defibrillation
desired for SCD
● CRT or CRT/D?
● Re-evaluate medication and compliance
● Re-evaluate for precipitating factors,
and coexistent conditions
● Diuretics¡euvolemia
● Evaluate for heart transplant
● Evaluate for destination LVAD
● Meticulous fluid management
● Inotrope trial if hypotensive and volume-
overloaded (LVSD)
● Intravenous nitrates/hydralazine?
● Discontinue medications not impacting
symptoms
● Continue ACE inhibitor or ARB, titrate beta-
blocker dose, or stop if hypotensive
● Diuretics¡euvolemia
● Inotrope trial if hypotensive and volume-
overloaded
Decision-making ● Preferences for
CPR/defibrillator
● Durable power of attorney for
health care or proxy
● Defibrillator for primary prevention of
SCD?
● Durable power of attorney for health
care or proxy decision-maker
● General goals for care, preferences for
unacceptable health states
● Urgent care decisions using doctor’s best
judgment or clear patient preferences
● Are advanced or invasive therapies
indicated?
● Are advanced therapies consistent with
patient preferences?
● Candidate for transplant or destination
VAD?
● Is palliative care appropriate?
● Does patient benefit from inotrope infusion?
● Review preferences for CPR/defibrillator
● Clarify goals of care
● Site of care (hospital, home, other)
● Health care delivery (hospice, other provider)
● How to manage death (review CPR decision,
review ICD and other devices; if appropriate,
plan deactivation)
Supportive care
A. Communication
● Understand patient concerns
and fears
● Identify life-limiting nature of HF
● Elicit preferences for care in
emergencies or sudden death
and for information and role in
decision-making
● Elicit symptoms and assess
QOL
● Elicit symptoms and assess QOL
● Re-evaluate resuscitation preferences
for care in emergencies
● Set goals for care
● Identify coping strategies
● Re-educate about sodium, weight, and
volume status
● Elicit symptoms and QOL
● Elicit values and re-evaluate preferences
● Identify present status and likely
course(s)
● Re-evaluate goals of care
● Re-educate about sodium, weight, and
volume status, medication compliance
● Elicit symptoms
● Acknowledge present status
● Elicit preferences and reset goals of care
● Identify worries
● Review appropriate care options and likely
course with each
● Explore suitability and preferences about
surgery or devices
● Elicit desired symptom relief and identify
medication for symptom goals
● Assistance with delivery of care
● Preferences for end-of-life care, site of care,
family needs, and capabilities
● Plan after death (care of the body,
notifications, memorials, burial)
B. Education ● Patient and family self-
management (sodium, weight
and volume)
● Diet, exercise
● HF course including sudden
death and options for
management
● What to do in an emergency
● Review self-management
● Review self-management
● Review what to do in an emergency
● Symptom management
● Eliminate NSAIDs
● Optimal management for given care
approach
● Interventions for deterioration in status
● What to do in an emergency
● Likely course and plans for management of
events
● Symptom management
● What to do for worsened or change in status
● What to do when death is near and at the
time of death
C. Psychosocial
and spiritual
issues
● Coping with illness
● Insurance and financial
resources
● Insurance and financial
resources regarding medications
and loss of income
● Emotional and spiritual
support
● Roles and coping for patient and family
● Emotional support
● Spiritual support
● Social interaction
● Evaluate both patient and family
anxiety, distress, depression, impaired
cognition
● Family stresses and resources
● Re-evaluate patient and family needs
● Caregiver education and assistance with
care
● Evaluate cognition and initiate
compensation
● Insurance coverage
● Re-evaluate stresses, needs, and support
patient and family
● Address spiritual and existential needs
● Support coping with dying
For both patient and family:
● Address anxiety, distress, depression
● Address spiritual and existential needs,
concerns regarding dying
● Anticipatory grief support
● Assist in care provision
● Post-death bereavement
D. Symptom
management
● HF medications for dyspnea
● Exercise/endurance training
for fatigue
● Antidepressant for depression
(check Na with SSRIs)
● Local treatment and/or opioids
for pain
● Identify new or worsened symptoms
● CPAP/O2 for sleep-disordered breathing
● Exercise program (lower extremity
strengthening)
● Local treatment and/or opioids for pain
● SSRI or tricyclic or stimulant for
depression
● Oxygen for dyspnea; consider opioids for
acute relief of dyspnea
● Lower extremity strengthening for
dyspnea/fatigue
● CPAP/O2 for sleep-disordered breathing
● Local treatment and/or opioids for pain
● SSRI or tricyclic or stimulant for
depression
● Oxygen for dyspnea
● Opioids for dyspnea
● Lower extremity and inspiratory
strengthening
● CPAP/O2 for sleep-disordered breathing
● Local treatment and/or opioids for pain
● Benzodiazepines/counseling for anxiety
● Stimulant for depression
● Opioids for dyspnea and pain
● Oxygen for dyspnea
● Stimulants for fatigue
● Benzodiazepines/ counseling for anxiety
● Lower extremity strengthening for fatigue
and dyspnea
● CPAP/O2 for sleep-disordered breathing
● Stimulant for depression
Coexistent conditions: atrial fibrillation with uncontrolled rate, sleep-disordered breathing, anemia, physical frailty, coexistent pulmonary disease.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; CPAP continuous positive airway pressure; CPR cardiopulmonary resuscitation; CRT cardiac resynchronization therapy; CRT/D cardiac resynchronization therapy defibrillator; EF ejection
fraction; HF heart failure; ICD implantable cardioverter-defibrillator; LVADleft ventricular assist device; LVEF left ventricular ejection fraction; LVSD left ventricular systolic dysfunction; NSAID nonsteroidal anti-inflammatory drug; NYHA New York Heart Association;
QOL  quality of life; SCD  sudden cardiac death; SSRI  selective serotonin reuptake inhibitor; VAD  ventricular assist device.
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July 28, 2009:386–96 Palliative Care for HFesistance, cachexia, and anorexia, and contributing to the
atabolic state (12). These hormonal and cytokine alter-
tions result in respiratory and skeletal muscle atrophy and
eakness, which contribute to symptoms of fatigue, dys-
nea, and limited exercise capacity. The muscle abnormal-
ties in HF are quite similar to “sarcopenia” of aging (13),
hich also likely relates to abnormalities of the renin-
ngiotensin-aldosterone system (14), and proinflammatory
bnormalities common in the aged. Because the vast ma-
ority of HF patients are elderly, there is significant overlap
etween HF and other prevalent conditions in aging. The
nderlying neurohormonal and cytokine derangement, my-
pathy and other abnormalities have been well-described in
oung HF patients and therefore play a significant role in
he pathophysiology of HF symptoms.
Heart failure patients have increased ventilatory rates for
given volume of expired carbon dioxide (VE/VCO2) that
ause tachypnea for a given work load, but are independent
f symptomatic dyspnea. Dyspnea (the perception of diffi-
ulty breathing) may not be subjectively present in HF
atients despite increased respiratory rate. The ergoreflex in
uscle (in response to work, ergoreceptors stimulate venti-
Figure 2 Schematic Etiology of Heart Failure Symptoms
Figure illustration by Rob Flewell. RAAS  renin-angiotensin-aldosterone system; Tation and activate sympathetic hormones) impact ventila- bory effort as do central and pulmonary chemoreceptors
which respond to carbon dioxide) and pulmonary J recep-
ors (that likely respond to congestion or alveolar stiffness).
vert pulmonary edema is associated with dyspnea, and its
elief with improvement in dyspnea, although left ventric-
lar function or volume status per se do not relate specifi-
ally to exercise capacity, fatigue, or dyspnea (15).
Sleep-disordered breathing, which is present in approxi-
ately one-half of HF patients, complicates HF manage-
ent and contributes to daytime fatigue. Oxygen desatura-
ion causes marked elevations in norepinephrine that in turn
ontribute to anxiety and depression, as well as worsen
ympathetic derangement. Cognitive impairment is preva-
ent in HF. Impaired memory and executive function, the
bility to relate and sequence information, cause difficulty
ecognizing worsened HF status and complying with the
omplex medication regimen for HF. Comorbid obesity,
ulmonary disease, or frailty may also contribute to the
ymptom spectrum in HF.
ssessment of symptoms. The New York Heart Associa-
ion (NYHA) level has been used as a proxy for symptom
ssessment in HF; however, this scale is a general statement
umor necrosis factor.NF  ty the clinician reflecting physical function and symptom
s
n
c
p
u
m
E
M
p
d
T
v
0
i
H
p
p
d
1
c
a
i
i
a
f
c
A
a
o
a
e
m
W
C
K
a
p
M
t
s
f
a
o
t
p
P
H
a
n
s
d
t
m
F
t
r
a
m
c
s
c
I
i
i
e
s
t
p
v
I
i
u
c
L
p
t
a
V
s
p
D
t
s
t
o
c
c
d
v
v
t
p
i
r
e
s
r
r
b
i
m
s
b
a
a
390 Goodlin JACC Vol. 54, No. 5, 2009
Palliative Care for HF July 28, 2009:386–96everity. Physician and patient report of NYHA status do
ot correlate well (16), and NYHA also differs from a
lassification based on metabolic equivalents assigned to
atient-reported activity (17). Tools to assess symptoms
sed in HF patients include the Memorial Symptom Assess-
ent Scale (MSAS) (18), modified for HF (19), and the
dmonton Symptom Assessment Scale (ESAS) (20). The
SAS-HF is a 32-item tool that rates frequency over the
revious 2 weeks of symptoms, as well as their severity and
istress, but its complexity and length may limit clinical use.
he ESAS, which rates severity of 9 symptoms using a
isual analog scale (a 100-mm line anchored by labels at the
[none] to 10 [worst possible] marked by the patient to
ndicate their status), has been administered to advanced
F patients (21), or modified as a 4-point scale (labeled not
resent, mild, moderate, and severe) administered to older
atients with HF (22). In rating symptom severity, patients
iscriminate better with a 5-point numerical scale than a
0-point scale (23). For clinical use, the ESAS or a rating of
ommon symptoms on a 5-point scale are appropriate to
ssess symptoms throughout the course of illness. A clinical
nterview should identify factors that precipitate, worsen, or
mprove each symptom, and in the case of pain, its location
nd character.
Clinical research should include patient reports of symptom
requency, severity, and interference in activity or distress
aused by the symptom, in relation to the intervention studied.
working group of trial cardiologists recommends a “provoc-
tive dyspnea assessment” using a 5-item scale at multiple levels
f activity to give a “dyspnea severity scale” from 1 to 25,
lthough this is not tested or validated (24).
The majority of trials of therapies in HF have not
valuated symptoms as outcomes. Three research tools
easuring HF-related quality of life, the Minnesota Living
ith Heart Failure (MLWHF) questionnaire (25), the
hronic Heart Failure (CHQ) questionnaire (26), and the
ansas City Cardiomyopathy Questionnaire (KCCQ) (27),
re sensitive to changes in clinical status. All 3 tools ask the
atients to rate how their HF has affected activities and the
LWHF and CHQ ask how HF impacts symptoms; thus,
hey are limited by the patient’s interpretation that a
ymptom or problem relates to HF. The KCCQ asks
atigue, shortness of breath, and swelling frequency, and
mount they bothered over 2 weeks. A single-center study
f persons with advanced HF found a correlation between
he ESAS combined “symptom distress score” and KCCQ
hysical symptom score (24).
alliation of symptoms. The pathophysiologic basis for
F-related fatigue, dyspnea, and compromised exertion
rgues for the use of treatments that block or modify the
eurohormonal and cytokine abnormalities of HF to palliate
ymptoms. Many pharmacologic and device studies have
ocumented improvement in NYHA functional classifica-
ion and/or HF-related quality of life along with improve-
ents in neurohormonal activation with the intervention.
ew studies specifically assessed change in patient symp- poms, rather than NYHA functional classification or HF-
elated quality of life.
In addition to therapies targeting the neurohormonal
lterations in HF, other interventions have been docu-
ented to provide specific benefits. Many interventions
ommonly employed in palliative care have not been tested
pecifically in HF, but merit consideration by clinicians
aring for HF patients.
nterventions to address the neurohormonal alterations
n HF and symptoms. Angiotensin-converting enzyme
nhibitors as a drug class improve HF patient duration of
xercise (28), and presumably also as a class, improve HF
ymptoms. An early double-blind randomized trial of cap-
opril demonstrated statistically significant improvement in
atient rating of dyspnea, fatigue, orthopnea, and edema
ersus placebo in patients with NYHA functional class II to
II HF (29). In this study, just under two-thirds of subjects
mproved with captopril, however, and one-third were
nchanged. All angiotensin-converting enzyme inhibitors
an be expected to improve symptoms in patients with
VSD. Studies in patients with HFnEF are limited, but
erindopril in elderly HFnEF patients resulted in a statis-
ically significant improvement in NYHA functional class
nd 6-min walk distance (30). A secondary analysis of
al-HeFT (Valsartan Heart Failure Trial) data demon-
trated that valsartan improved composite fatigue and dys-
nea scores versus placebo in patients with LVSD (31).
ata about other angiotensin receptor blockers and symp-
oms are otherwise not available.
Beta-blockers as a class have variable impact on HF
ymptoms and overall quality of life (32), possibly relating to
heir adrenergic blocking profiles. A small randomized trial
f carvedilol in advanced HF patients documented signifi-
ant improvement in a 7-point symptom scale versus pla-
ebo (33), and a multicenter randomized controlled trial
ocumented marked (21.1% vs. 16.1%) or moderate (28.5%
s. 23.9%) improvement in a global score for carvedilol
ersus placebo (34).
Whereas the RALES (Randomized Aldactone Evalua-
ion Study) trial demonstrated statistically significant im-
rovement in NYHA functional class with spironolactone
n patients with advanced LVSD HF, only 41% of those
eceiving spironolactone improved, and 38% of them wors-
ned (35). These modest results and absence of data about
pecific symptoms suggest that a cautious trial of aldoste-
one blockade is warranted with monitoring of patient-
eported symptoms to assess individual benefit. Aldosterone
lockade may help manage volume overload in addition to
ts neuroendocrine action. Serum potassium levels must be
onitored when spironolactone is initiated. Investigation of
pironolactone in HFnEF is in progress.
All HF patients should be screened for sleep-disordered
reathing in light of the over 50% prevalence in HF patients
nd the impact of sleep-disordered breathing on symptoms
nd right and left ventricular function (36). Continuous
ositive airway pressure (CPAP) reverses the adverse neu-
r
w
(
c
w
w
n
b
i
d
l
O
p
b
a
p
o
L
i
t
a
T
c
B
m
c
a
s
f
e
t
c
p
d
s
m
u
a
N
d
a
P
s
u
i
t
c
e
t
d
a
c
d
t
t
e
o
o
e
h
t
h
a
m
d
a
p
s
a
a
c
f
e
i
b
t
A
s
s
(
a
a
i
e
I
t
e
S
m
e
i
L
w
a
C
j
i
b
a
o
c
d
j
391JACC Vol. 54, No. 5, 2009 Goodlin
July 28, 2009:386–96 Palliative Care for HFohormonal activation for patients with sleep apnea and
ith Cheynes-Stokes (or periodic breathing) respiration
37). CPAP improves emotional function, fatigue, sense of
ontrol or mastery, social function, and vitality in patients
ith LVSD and sleep apnea (38). Heart failure patients
ith periodic breathing have improved quality of life with
octurnal oxygen supplementation (39). Sleep-disordered
reathing treatment with CPAP or oxygen supplementation
s warranted to improve symptoms at all phases of HF care,
espite debate about the impact about these treatments on
ongevity.
ther treatments to palliate symptoms. Loop diuretics
rescribed for volume overload in HF improve exertion and
reathlessness (40), but activate the renin-angiotensin-
ldosterone system, so they potentially exacerbate HF
athophysiology (41). Early in HF treatment and at points
f decompensation, aggressive diuresis in patients with
VSD results in decreased patient reported dyspnea and
mproved global status (42). Diuretics to achieve and main-
ain euvolemia are considered important to symptom man-
gement throughout the course of both LVSD and HFnEF.
he clinical assessment of volume status is a key skill for
linicians at all phases of HF care, including the end of life.
-type natriuretic peptide measurement is controversial but
ay help identify volume overload. Patients, families, and
linicians should routinely use weight as a proxy for volume,
djusting diuretics to maintain a euvolemic target weight.
Dietary intervention that specifically restricts fluids and
odium intake reduces fatigue and edema (43). Education
or patients about HF and their management of sodium,
xercise, and medications must be repeated and reinforced
hroughout the course of care for HF patients (44), espe-
ially at times of exacerbation. At all phases of HF care,
atients and families should understand management of
ietary sodium and fluid status as a means to improve
ymptoms. In addition, restricting fluid and sodium intake
ay reduce the need for diuretics and associated urinary
rgency.
Oral nitrates are commonly prescribed to HF patients,
lthough their impact on specific symptoms is not known.
o evidence supports the use of oral nitrates to relieve
yspnea, but intravenous nitroglycerine relieved dyspnea in
randomized controlled trial for decompensated HF (45).
articularly when ischemia or overt volume overload are
uspected, trial of oral or transdermal nitrates in an individ-
al patient may be warranted.
In small randomized controlled studies, oral opioids
mprove dyspnea acutely and chronically in NYHA func-
ional class II to IV patients, without significant adverse
onsequences. Opioids improve the ventilatory response to
xercise (46–48). Several mechanisms may be important in
he effect of opioids on dyspnea: they variably cause vaso-
ilation, act on opioid receptors in the brain and in the lung to
lter the perception of dyspnea, and are anxiolytic. Dihydro-
odeine alters arterial chemosensitivity to oxygen and carbon
ioxide in exercising HF patients. Opioids are appropriate for she relief of dyspnea at all phases of HF care. Other interven-
ions that impact chemosensitivity, such as caffeine, improve
xercise endurance (49), so they may have a role in treatment
f exertional dyspnea or fatigue.
Patients with HF and depression report more fatigue and
ther symptoms than those without depression (50). The
vidence base to direct choice of antidepressants is weak;
owever, patients with renal impairment treated with selec-
ive serotonin reuptake inhibitors (SSRIs) are at risk for
yponatremia or fluid retention, likely due to increased
ntidiuretic hormone, so serum sodium must be carefully
onitored (51). Tricyclic antidepressants (nortriptylene or
esipramine) are appropriate alternatives to SSRIs, but have
quinidine-like effect on conduction, and at high doses can
rolong QT intervals. Both SSRIs and tricyclic antidepres-
ants require 2 weeks or longer to titrate. Methylphenidate
nd other psychostimulants have minimal adverse effects
nd have been used effectively in the elderly and in other
hronic life-limiting illnesses for treatment of depression or
atigue. Benefit from psychostimulants is seen in 1 to 2 days.
Anxiety has not been well evaluated in HF; however,
ngaging spouses and increasing spousal sense of control
mproves HF patient emotional distress (52). Patients with
etter self-assessed control over their HF have less emo-
ional distress as well as better exertional performance (53).
prospective cohort study combining a “mindfulness”
upport group and HF education resulted in statistically
ignificant improvement in depression and anxiety scores
54). Benzodiazepines (such as lorazepam, which has no
ctive metabolites and a 4 to 6 h length of action) are
ppropriate for treatment of distressing anxiety at any point
n HF care.
Several studies demonstrate the benefit of exercise to
ndurance and quality of life in HF patients (55,56).
nspiratory respiratory muscle training improves blood flow
o resting and exercising skeletal muscles, and improves
xercise performance and dyspnea in HF patients (57–59).
pecific thigh muscle training improves dyspnea as well as
uscle strength (60), and should be the cornerstone of HF
xercise programs. In a single-center trial, aerobic exercise
mproved the apnea–hypopnea index in patients with
VSD and sleep-disordered breathing (61). In HF patients
ith anemia, erythropoietin enhances exercise capacity (62).
Although pain is common in HF patients, its etiology
nd appropriate treatment remain to be elucidated (63).
hest pain is common, as is pain in other sites, with leg and
oint pain predominating (64). Nonsteroidal anti-
nflammatory drugs are contraindicated in HF patients
ecause these drugs impact kidney function, cause sodium
nd fluid retention, and worsen HF (65–67). Osteoarthritis
r chronic musculoskeletal pain can be treated with a
ombination of muscle-strengthening exercises, assistive
evices, modalities (heat, cold, ultrasound), intra-articular
oint injection, and opioids.
Opioids have diverse effects in the cardiovascularystem, as well as the nervous and endocrine systems
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Palliative Care for HF July 28, 2009:386–96such as regulation of vasopressin). Opioids can be safely
dministered to HF patients in cardiac anesthesia, al-
hough these drugs variably cause bradycardia, hypoten-
ion, and suppression of respiratory drive, so these effects
hould be monitored with parenteral administration.
General principles of opioid prescription are to: 1) begin
herapy with short-acting opioids and titrate to the amount
f pain relief desired by the patient; 2) treat intermittent
ain with intermittent medication, and chronic or persistent
ain with around-the-clock or long-acting opioids; and
) accompany all opioid prescriptions with a stimulant
axative prescription. Morphine, codeine (and possibly hy-
romorphone) have active renally cleared metabolites that
ause delirium and myoclonus, and are therefore appropriate
nly for intermittent use in HF patients. Fentanyl and
ethadone do not have active metabolites; however, each
as unique issues. Fentanyl is approved only for use in
pioid-tolerant patients in either oral-buccal mucosal or
ransdermal delivery systems. Methadone accumulates in
issues, and the dose and interval must be titrated for 5 to 7
ays when it reaches a steady state. Methadone can variably
rolong rate-corrected QT interval and rarely cause torsades
e pointes (usually at doses 100 mg/day), so electrocar-
iograms should be evaluated at baseline and 30 days after
nitiation of methadone (68).
In patients with reduced systolic function, inotrope ther-
py may improve quality of life, despite increased risk of
udden death (69,70). Cardiac resynchronization therapy
71) and destination left ventricular assist devices (72)
mprove exertion and HF-related quality of life for select
atients, although data about their impact on specific
ymptoms are not available.
ommunication with patients about dying and approach
o care. Although the focus of therapy for many patients
s to improve function and defer death, the life-limiting
ature of HF and increased risk of sudden cardiac death
SCD) with HF should be acknowledged at the time of
lements of Communication About Prognosis With Heart Failure PaTable 2 Ele ents of Communication About Prognosis With Hea
“Bad news” conversation Plan the delivery of sad or unexpected
Ask-Tell-Ask Ask what the patient understands (bef
Correct misunderstanding and
Tell your information.
Ask what questions they have, clarify i
Simple, honest language
Simple statistics
Ground data in more than 1 way
Define medical terms. Speak plainly an
people. . .”).
Describe both chance of death and cha
Hope for best, plan for the worst
“Both-And”
Ask what the patient hopes for, and id
Plan for death or other bad outcomes
Create a dichotomy and address both
Normalize uncertainty Acknowledge that we can’t know for su
Partner and plan Tell the patient you (or your team) will
Deliver length of life in broad range Provide a broad range “months to year
Empathize Name your emotions (“I feel sad”), and
“many would feel angry”).
Follow-up Summarize the plan and set an appoinF diagnosis as part of HF patient/family education o73). Providing HF patients and families a warning that
eath may come suddenly or with chronic illness helps
emove surprise from later communication when the
atient deteriorates or at the end of life (74). Knowledge
f the life-limiting nature of HF may also help patients
nd their families “fight” HF by diet, exercise, and
edications, in addition to helping them “plan for the
orst” should they die sooner than preferred. The subject
f dying need be only reviewed when the patient inquires,
t is required for decision making about interventions, or
ith a decline in status. Physicians and nurses should be
repared to discuss dying and prognosis whenever they
rise. Answers about prognosis, should be honest, and
ncertainty should be acknowledged. Discussions with
F patients about length of life should give a range of
ime, and should acknowledge the possibility for error at
ither end.
All HF patients and their families should have a plan to
anage potential SCD, including in selected LVSD pa-
ients once HF therapy has been optimized, potentially
ife-prolonging interventions such as implantable cardio-
erter defibrillators. Basic approaches to giving bad news,
articipatory decision making, and communicating about
he end of life should be learned by all clinicians caring for
F patients. These are presented in detail in another review
71), but key aspects are outlined in Table 2. Training in
hese specialized communication skills integrated into on-
ology fellowships and continuing education (75), should
erve as a model for cardiology.
Preferences for approach to care in advanced disease
ay be more related to educational level and health
iteracy or the length of discussions than to race or ethnic
ackground. Allowing for discussions over time or using
ools such as videos reduces disparities (76). The Ask-
ell-Ask framework is particularly important when car-
ng for patients of different ethnic or racial groups from
s and Familiesilure Patients and Families
ation, and warn the patient that you have bad news; follow the points below.
u talk).
tion.
id euphemisms and relative statistics or percentages. Use numbers (“1 out of 5
f life.
hat you can also hope for.
gs do not go as we hope.”
e many things in life.”
ith them to meet specific goals.
allow for error on either end.
ify emotions the patient expresses or might reasonably have (“you look surprised,”
to follow-up on plans and their status.tientrt Fa
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ore yo
nforma
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“if thin
issues.
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July 28, 2009:386–96 Palliative Care for HFecision making should be asked to appoint someone to
ake decisions on their behalf.
nd-of-Life Care for HF Patients
he “end of life” for a given HF patient is not easily predicted
y clinical data or symptoms. Nurses’ predictions of death for
ospitalized HF patients in a large multicenter trial were better
han a prognostic model (incorporating blood urea nitrogen,
ystolic blood pressure, and 6-min walk score) (77). In a
ommunity study, symptom prevalence did not distinguish
YHA functional class III to IV patients who died from those
ho survived 1 to 2 years (78). Risk models may identify
atients at high likelihood of death in 6 to 12 months,
lthough these models have not been prospectively tested
79,80). In a single center, HF patients did not perceive the
ife-limiting nature of HF (81). In combination, these barriers
upport providing palliative care to all HF patients, and
cknowledging HF as a life-limiting illness, even when work-
ng toward patient and family goals to prolong life.
The course to death in patients should not be character-
zed by severe dyspnea or volume overload. Rather, most
ying patients managed by HF specialists experience met-
bolic derangement and coma, or sudden death (82,83), not
ongestion and dyspnea. Heart failure patients make deci-
ions about treatments based on a description of what their
ourse might be and mode of death, in addition to likely
enefits and burdens (84,85). In time tradeoff or treatment
radeoff studies, patient decisions are not necessarily related
o their HF status or symptom severity (86,88), and often
hange over time (87). How these hypothetical choices
elate to real-life decisions is not known.
Physicians lack experience in discussing decisions such as
eactivation of implanted defibrillators at the end of life
88), yet patients experiencing 5 or more shocks have poor
uality of life (89), and may want an option to deactivate the
evice. Advanced HF patients who prefer to be allowed to
ie naturally when the time comes should have a defibril-
ator electively deactivated. Any center that implants defi-
rillators should have a clearly defined process for their
eactivation. A decision to discontinue or forego a treat-
ent such as defibrillation is ethically and legally equivalent
o a decision to initiate a treatment (90), and follows the
ame informed decision-making process. Clinicians caring
or HF patients must acquire the skills to make decisions
bout care based on the patient’s preferences and the likely
enefit and burden of therapies for that individual.
anagement at the end of life. Advanced HF should
rovoke a re-evaluation of medications, dietary sodium
onsumption, and interventions that might improve the
atient’s status (91). At a shift in focus of care, such as the
nd of life, clinicians ought to re-evaluate all treatments
elative to the goals of care, and discontinue therapies that
re burdensome or that do not provide symptomatic relief.
ecause medications and treatments that address the neu-
ohormonal and sympathetic disarray in HF improve symp- soms, these should be continued to the extent that blood
ressure and function tolerate. No studies have evaluated
he impact of dose reduction on symptoms. In a single
enter, in significantly volume-overloaded patients with
dvanced HF, carvedilol initiation and up-titration was
etter tolerated and associated with lower rates of death,
ospitalization, or study drug withdrawal, than placebo
92). Until data about symptoms and well-being are avail-
ble about HF medications at the end of life, clinicians will
eed to decide about medication continuation with individ-
al patients and families based on their individual goals of
are.
Studies of palliative care programs that included HF
atients have not characterized either the patients’ HF
tatus or use of evidence-based medications, but the pro-
rams improved dyspnea, anxiety, and spiritual well-being
93), caregiver satisfaction, and increased rates of death at
ome (94). When HF clinicians identify patients’ or fami-
ies’ worries, fears, and spiritual and existential issues, the
linicians may create a “virtual team” using resources from
he community and other clinicians to provide interdiscipli-
ary support.
Bereavement support, for losses in function and social
oles throughout HF and at the end of life in anticipation of
eath, is an area where additional research is needed.
imilarly, support for spiritual and existential issues in HF
ill benefit from more investigation. Clinicians should
nquire about and acknowledge concerns, and identify
esources to support the patient and family. Throughout
are, maintaining contact, even by brief notes or telephone,
s valued by patients and families. After death, a note or
elephone call from clinicians to the family to express
ondolences is important to the family and as closure for the
linician (74).
ospice care for HF patients. Reimbursement models
mphasize a false dichotomy in which hospice or formal
alliative care is expected to begin and HF care cease at
ome difficult-to-identify point. In a secondary analysis of
atients hospitalized with acutely decompensated HF, rates
f discharge from hospitals to hospice were very low,
lthough they varied by geographic region (95). Patients
ischarged to hospice in this study were remarkably similar
o those who died in the hospital, except that patients who
ied had significantly more invasive procedures than those
ent to hospice.
Hospice care for HF patients varies among agencies:
ospices generally provide oral medications for HF and
pioids for symptom management, but few hospices, gen-
rally those with large patient censuses, provide more
omplex and expensive treatments such as intravenous
edications or inotropes (96). Hospice nurses lack knowl-
dge and self-assessed competency about HF management
97). Good end-of-life care for HF patients will require
linicians with HF expertise to work directly with hospice
taff to collaboratively manage care and to improve hospice
taff knowledge and skills regarding HF.
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Palliative Care for HF July 28, 2009:386–96Once enrolled in the Medicare hospice benefit, the length
f care is not limited; however, at the end of specified
eriods, hospices must discharge the patient or recertify him
r her as likely to die within 6 months. Prognostic tools may
e helpful in patient re-evaluation, particularly when, with
areful management, the patient’s status has improved.
atients may elect to revoke the hospice benefit at any time
ecause they desire a different approach to care. When
ospice care ceases for either reason, it is appropriate to
e-evaluate the patient’s status and preferences and reclarify
oals for care. A palliative focus often remains appropriate.
onclusions
omprehensive HF care should integrate palliative care
hroughout the course of management. The etiology of
any HF symptoms relates to neurohormonal and cytokine
ctivation, and the resulting impact on skeletal and respira-
ory muscles. Interventions to palliative symptoms include
vidence-based therapies for the neurohormonal derange-
ent in HF, but data about therapies that specifically
mprove symptoms are sparse. Evidence supports some
ther interventions, including specific exercise and opioids
or dyspnea, but additional data are needed to inform
reatment of depression, anxiety, pain, and spiritual distress,
mong other problems, in HF patients and their families.
Data regarding symptom relief should be included in
linical trials for HF, and specifically to understand pallia-
ive therapies in advanced HF. Palliative care for HF should
ncorporate evidence-based HF therapies and interdiscipli-
ary interventions to address multiple domains of patient
nd family distress.
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